Headaches & Migraines

Monika Kujawska et al. (2019) · Journal of ethnobiology and ethnomedicine

This historical review examined Bryonia alba (white bryony), a vine in the cucumber family, tracing its use across northern and central-eastern Europe from antiquity through the twentieth century. The authors, an ethnobiologist and an ethnologist, worked from written and oral sources rather than a clinical study, covering Sweden, Denmark, Germany, Poland, Belarus, Ukraine, Romania and the Balkans. White bryony's root closely resembles the root of mandrake (Mandragora officinarum), a plant with an extensive European magical and medicinal reputation; the paper's central finding is that this resemblance let bryony function as mandrake's cheaper stand-in, inheriting much of its folklore in the process. Rather than enrolling participants, the authors searched historical floras, pharmacopoeias, ethnographic monographs, and travel accounts for every mention of the plant, then sorted findings into categories: ritual and folk-belief use, food, folk and historical medicine, ethnoveterinary practice, and ornamental planting. They cross-checked, where sources allowed, whether a given account referred to B. alba or its close relative B. dioica, and separated practices documented only in printed herbals ("booklore") from those recorded as living oral tradition passed between households. Across independent sources, root preparations were repeatedly recorded for oedema (fluid swelling, called dropsy at the time), convulsions and epilepsy, intestinal worms, wounds, and rheumatic pain — a 1792 Swedish account describes juice collected from a hollowed-out root curing oedema and treating worms, convulsions and headache, while twentieth- and twenty-first-century accounts from Serbia and Kosovo describe the same root used as a purgative, diuretic and topical anti-rheumatic agent. The authors cite phytochemical literature attributing these effects to cucurbitacins (bitter plant compounds), also linked elsewhere to antitumor activity, while stating plainly that historical claims for epilepsy specifically lack sufficient supporting study. Toxicity is dose- and season-dependent: freshly harvested summer root contains the more toxic cucurbitacin I, and the berries carry a cited lethal dose of roughly 15 for a child and 40 for an adult. The authors report that medicinal use had become obsolete across Scandinavia, Germany and western Slavic regions by the twentieth century, surviving only in isolated Balkan communities in Serbia and Kosovo. The authors present this decline as an unusual case: a plant of substantial historical medicinal and magical importance that today survives mainly as an ornamental garden relic or, in North America, as an unrelated invasive weed. Because the review synthesizes historical and ethnographic records rather than testing the plant directly, it offers no controlled data on safety or effectiveness, and the authors themselves flag some recorded folklore as possibly the invention of root sellers rather than genuine tradition. Future work, the authors suggest, could extend this same source-based method to B. dioica across German-, Latin- and Celtic-speaking Europe.

Pamela M Rist et al. (2020) · Cephalalgia : an international journal of headache

This pilot randomized controlled trial with 61 adult women explored whether adding multimodal chiropractic care to enhanced usual care could feasibly be delivered to people with episodic migraine, and whether it might reduce how often migraines occurred. Multimodal chiropractic care combines several hands-on techniques — spinal manipulation (adjusting joint movement in the spine), joint mobilization, soft-tissue release, and posture correction — rather than spinal manipulation alone, the approach most prior migraine trials tested. Enhanced usual care meant continuing regular medical treatment plus migraine education materials and regular phone check-ins, giving both groups comparable attention from the study team. Participants were women ages 21 to 55 (average 36) having 4 to 13 migraine days a month, randomly assigned to receive up to 10 individualized chiropractic sessions over 14 weeks (29 women) or enhanced usual care alone (32 women). Chiropractors tailored treatment to each person's diagnosis — myofascial pain, spinal misalignment, or jaw dysfunction — drawing from a fixed menu of techniques. Migraine frequency, severity, and disability were tracked through daily logs and standardized questionnaires: the Migraine Disability Assessment (MIDAS), the Headache Impact Test (HIT-6), and a migraine-specific quality-of-life scale, completed at 14 and 18 weeks. Recruitment and safety looked encouraging: of 422 people screened, 61 enrolled over 20 months, 93% completed migraine logs, and no serious side effects occurred, though only 83% of chiropractic-group participants attended enough sessions to meet the study's own adherence goal (versus a target of 85%), so feasibility criteria were narrowly missed. Migraine days dropped substantially more with chiropractic care added, a difference of about 2 fewer migraine days per month than usual care alone (95% confidence interval -3.46 to -0.37, meaning the true benefit is likely real but its exact size is uncertain), and this advantage held up a month after treatment ended. Disability and headache-impact scores (MIDAS and HIT-6) improved significantly more with chiropractic care too. However, migraine severity, duration, medication use, and quality-of-life scores did not differ significantly between groups, and musculoskeletal stiffness was reported more often by the chiropractic group (21% versus 6%). For migraine sufferers seeking non-drug options, these results are promising but preliminary: the size of the migraine-day reduction was similar to what topiramate, propranolol, and erenumab achieve against placebo in prior research. Because participants and chiropractors knew who was receiving treatment, and the chiropractic group received more attention overall, some of the benefit could reflect that extra contact rather than the techniques themselves. The sample was small, all female, and drawn from one clinic, so a larger, multi-site trial is needed before multimodal chiropractic care can be recommended as proven migraine therapy.

Dilara Onan et al. (2025) · Journal of oral & facial pain and headache

Chronic tension-type headache (CTTH) -- headaches on 15 or more days a month for at least three months -- is thought to involve tight, tender muscles in the head, neck, and face, though scientists are not fully certain why it happens. This systematic review and meta-analysis pulled together randomized trials testing physiotherapy-style treatments -- things like massage, exercise, acupuncture, and relaxation training -- to see whether they actually ease CTTH symptoms. The researchers followed a pre-registered research plan and searched two major databases through mid-2024, aiming to answer a focused question: do these hands-on and movement-based approaches beat sham treatment, no treatment, or medication alone? Two physiotherapist researchers with PhD degrees independently screened 237 studies and settled on nine randomized trials -- ranging from 25 to 169 patients each, mostly women, treated for 3 to 12 weeks. The approaches tested included trigger point massage, electroacupuncture, relaxation with muscle-tension biofeedback, yoga, and neck-and-shoulder strengthening exercises, among others. Seven of the nine trials had comparable enough data to combine mathematically (meta-analysis), and each study's methodological rigor was scored using a standard 11-item checklist. When the researchers pooled the numbers, physiotherapy approaches meaningfully reduced headache intensity compared to control (a large, statistically significant effect), cut the number of headache days per month by more than one day on average, and shortened how long headaches lasted -- all statistically significant improvements. A fourth measure, day-to-day headache impact on daily life, trended in favor of physiotherapy but did not reach statistical significance. Looking at individual studies: electroacupuncture beat sham treatment for headache intensity; combining a hands-on release technique with ibuprofen worked better than ibuprofen alone; and yoga added to standard medical care outperformed medical care by itself on several measures. Importantly, though, the researchers rated their overall confidence in these pooled results as low to very low -- the studies were small, methods varied a lot between them, and most carried some risk of bias. No serious side effects were reported in any trial. The takeaway is cautiously encouraging: physiotherapy-based approaches -- especially those combining exercise, hands-on techniques, or relaxation training with standard care -- show a real signal for easing CTTH symptoms, and they appear safe. But because the underlying evidence is still thin and inconsistent, these findings should not be read as proof that any one specific technique is the best choice. The authors call for larger, more consistently designed trials before physiotherapy can be confidently recommended as a primary CTTH treatment, though the current evidence supports trying it as a reasonable, low-risk complement to standard care.

Shabei Xu et al. (2020) · BMJ (Clinical research ed.)

This randomized controlled trial with 150 participants, published in The BMJ, tackled the biggest criticism of acupuncture research head-on: that acupuncture only beats "sham" needling when the sham is badly designed. Seven hospitals in China enrolled adults with episodic migraine without aura who had never received acupuncture before, so nobody could tell true needling from fake by experience. Participants were randomized to twenty sessions of manual acupuncture (real needles at true points, with the classical rotation and lift-thrust manipulation), twenty sessions of non-penetrating sham (blunt needles at non-acupuncture points that never break the skin), or usual care alone, all over eight weeks. Blinding was formally tested and held — 79% of the real-acupuncture group and 75% of the sham group believed they had received penetrating needles, a statistical dead heat (P=0.891). Migraine days and attacks were counted in four-week blocks through week 20. Real acupuncture pulled ahead of sham, and the gap grew after treatment ended. By weeks 17–20, manual acupuncture had cut 3.9 migraine days per four weeks versus 2.2 for sham (adjusted difference −2.1 days, 95% CI −2.9 to −1.2, P<0.001 — meaning roughly two extra migraine-free days a month attributable to true needling), and attacks dropped by 2.3 versus 1.6 (P<0.001). Both needle groups beat usual care alone, which is itself informative: part of acupuncture's benefit comes from the ritual and attention of treatment, and part — the two extra migraine-free days — from the needling itself. No severe adverse events were reported, and 147 of 150 participants completed the analysis. For the millions of people with migraine who cannot tolerate preventive drugs — or prefer not to start them — this trial provides unusually clean evidence that manual acupuncture has a real, specific preventive effect beyond placebo. The benefit emerged gradually, months into follow-up, suggesting patience matters. The trial ran in a single country and followed patients only to week 20, so durability beyond five months remains an open question.

Ping-Tao Tseng et al. (2023) · Advances in nutrition (Bethesda, Md.)

This network meta-analysis pooled 40 randomized controlled trials with 6,616 migraine sufferers to answer a question few doctors are asked but many patients wonder: can fish-oil omega-3s genuinely compete with prescription drugs for preventing migraines? Migraine affects roughly one in ten people worldwide, and standard preventive medications work for only 40–50% of those who try them, often with side effects that drive people to quit. Network meta-analysis is a technique that connects every studied treatment through shared comparison arms — here, 40 trials from the United States, Iran, Brazil, France, Norway and beyond, covering omega-3 supplements (EPA and DHA, the two main long-chain omega-3 fatty acids) alongside FDA-approved preventives like topiramate, valproate, amitriptyline, and propranolol. Participants averaged 35 years old and 79% were women, matching migraine's real-world demographics. Treatments ran 8 to 16 weeks, with migraine frequency and dropout rates as the primary measuring sticks. High-dose EPA/DHA ranked first in the entire network on every efficacy measure. It cut migraine frequency more than any drug (standardized mean difference −1.36 versus placebo, 95% CI −2.32 to −0.39 — a large effect) and reduced attack severity even more decisively (SMD −2.23, 95% CI −3.17 to −1.30). Just as important, people stuck with it: dropout was identical to placebo (odds ratio 1.00), while every prescription preventive in the network lost more patients along the way. The trade-off for honesty: the omega-3 trials were smaller than the drug trials, and the confidence intervals around these estimates are wide. This analysis moves high-dose omega-3 supplementation from "can't hurt" folk advice to a first-line candidate with top-of-network evidence, most relevant where preventive-drug side effects have been limiting. The benefit tracked the high-dose regimens, not the small amounts found in a typical daily fish-oil capsule.

Andrew J Vickers et al. (2017) · The journal of pain

This meta-analysis pooled the raw, patient-by-patient data of 20,827 people from 39 rigorously screened randomized trials — the largest and most careful analysis of acupuncture for chronic pain ever conducted. Acupuncture is the Traditional Chinese Medicine practice of inserting fine needles at specific body points; classical theory describes it as regulating qi (the body's vital functional energy) flowing through meridians (the mapped channels of that flow), while researchers here tested it purely on outcomes. Only trials with airtight randomization were included, covering four conditions: back and neck pain, osteoarthritis, chronic headache, and shoulder pain. The team obtained original data from trial authors and re-analyzed everything centrally — a gold-standard approach that removes many shortcuts ordinary meta-analyses must take. Acupuncture beat both comparison types for every condition (p < .001 — highly unlikely due to chance). Against no-acupuncture care the effect was about 0.5 standard deviations — in plain terms, starting from pain of 60/100, patients ended near 30 with acupuncture versus 43 without, and half of acupuncture patients achieved 50% pain reduction versus 30% of controls. Against sham (fake) acupuncture the margin was smaller (≈0.2 SD), meaning needle placement is only part of the benefit — but sham could not explain it all. Benefits lasted, fading only about 15% by one year. Neck and shoulder pain responded best (effect sizes 0.83 and 0.57 versus sham), and more sessions produced more relief (p = 0.001). Notably, the pooled effect matches or beats common anti-inflammatory drugs, whose effect sizes run below 0.23 for the same conditions. The authors' bottom line, unchanged since: referring a chronic pain patient for a course of acupuncture is a reasonable clinical option — with real, persistent, not-just-placebo benefit and an excellent safety profile.